Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HarrowHROW +5.36%80 OCF Margin % is -13.81% as of Jun. 2026. GuruFocus rates HROW with a GF Score™ of 80/100 and a GF Value™ of $42.00 (Fairly Valued). The stock has 4 warning signs investors should review. Among 960 Drug Manufacturers companies, Harrow ranks worse than 68.23% on this metric.
The historical data trend for Harrow's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Harrow's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harrow OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Harrow's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Harrow's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harrow (HROW) has a OCF Margin % of -13.81% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Harrow and its competitors. According to the industry distribution chart, Harrow ranks #655 out of 960 companies in the Drug Manufacturers industry, placing it in the top 68.2%.
Is Harrow's OCF Margin % too high?
Harrow's current OCF Margin % is -13.81%. Based on the distribution chart, Harrow ranks #655 out of 960 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Harrow has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Harrow's OCF Margin % compare to XERS and PRGO?
According to the Drug Manufacturers industry distribution chart, Harrow ranks #655 out of 960 companies for OCF Margin %. This places Harrow in the lower half of its industry. The industry median OCF Margin % is 9.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.85, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Harrow and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harrow's current OCF Margin % is -13.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harrow stock overvalued right now?
Based on GuruFocus' analysis, Harrow (HROW) is currently considered Fairly Valued. The stock's GF Value™ is $42.00, compared to a current price of $41.64 — trading 0.9% below its estimated fair value. The current OCF Margin % is -13.81%. Harrow's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Harrow (HROW), the current OCF Margin % is -13.81% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harrow (HROW) Overvalued in 2026?
Based on GuruFocus' analysis, Harrow stock appears to be undervalued.
The current stock price of $41.64 is trading 0.9% below its estimated GF Value™ of $42.00.
GuruFocus considers Harrow to be Fairly Valued.
Key valuation signals for HROW:
OCF Margin %: -13.81%
GF Value™: $42.00 vs. price of $41.64 (0.9% below fair value)
No single metric tells the full story. See the HROW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
80GF Score
Get the complete analysis for HROW
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HROW has been successfully added to your 
